CLAIMS

1. A nucleic acid vector comprising a translation enhancer (TE) sequence having at least 80% sequence identity to SEQ ID N°1, a transcribable nucleic acid sequence and a nuclear retention sequence represented by SEQ ID N°4.

2. The nucleic acid vector according to claim 1, wherein said transcribable nucleic acid sequence is selected from the list comprising mRNA encoding CD40L, CD70, caTLR4 or antigen/disease specific mRNA.

3. The nucleic acid vector according to anyone of claims 1-2, wherein said translation enhancer is represented by SEQ ID N° 1.

4. A method of increasing stability and/or translation efficiency of *in vitro* transcribed RNA; said method comprising the steps of:

    (i) providing a vector according to anyone of claims 1-3, wherein said transcribable nucleic acid sequence is a transcribable DNA sequence, which corresponds to said RNA to be transcribed; and
    (ii) transcribing *in vitro* said transcribable DNA sequence.

5. An RNA molecule comprising a translation enhancer (TE) having at least 80% sequence identity to SEQ ID N°1, a transcribable nucleic acid sequence, and a nuclear retention sequence represented by SEQ ID N°4.

6. An RNA molecule according to claim 5 further comprising a poly-A tail.

7. An RNA molecule according to anyone of claims 5 or 6, wherein said transcribable nucleic acid sequence is selected from the list comprising mRNA encoding CD40L, CD70, caTLR4 or antigen/disease specific mRNA.

8. An RNA molecule according to anyone of claims 5-7, wherein said translation enhancer is represented by SEQ ID N° 1.

9. A composition comprising one or more RNA molecules as claimed in anyone of claims 5-8.

10. The composition according to claim 9, wherein said one or more RNA molecules represent mRNA molecules which encode CD40L, CD70 and caTLR4.

11. The composition according to claim 10 further comprising mRNA encoding antigen/disease specific mRNA.

12. The use of an RNA molecule according to anyone of claims 5-8, or the composition according to anyone of claims 9-11 for introduction in a host cell *in vitro*.

13. An RNA molecule according to anyone of claims 5-8 or a composition according to anyone of claims 9-11 for use as a medicament.

14. A kit comprising one or more vectors according to anyone of claims 1-3; one or more RNA molecules according to anyone of claims 5-8; or a composition according to anyone of claims 9-11.